Metsera (NASDAQ:MTSR) Price Target Raised to $62.00

Metsera (NASDAQ:MTSR - Free Report) had its price objective boosted by Guggenheim from $56.00 to $62.00 in a research note published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also recently issued reports about the stock. Bank of America initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price objective for the company. Evercore ISI began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating for the company. Finally, Cantor Fitzgerald began coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an "overweight" rating for the company.

Metsera Trading Down 15.0%

Shares of Metsera stock traded down $5.20 during trading on Tuesday, hitting $29.38. 809,806 shares of the stock were exchanged, compared to its average volume of 909,801. The business's 50-day simple moving average is $24.39. Metsera has a 12-month low of $12.30 and a 12-month high of $37.99.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Metsera

A number of institutional investors and hedge funds have recently bought and sold shares of MTSR. Strs Ohio purchased a new stake in Metsera in the first quarter valued at $76,000. New York State Common Retirement Fund purchased a new stake in Metsera in the first quarter valued at $131,000. Corebridge Financial Inc. purchased a new stake in Metsera in the first quarter valued at $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Metsera in the first quarter valued at $248,000. Finally, MetLife Investment Management LLC purchased a new stake in Metsera in the first quarter valued at $254,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.